4-1BB (CD137) in anticancer chimeras

Melero, I. (Ignacio); Berraondo, P. (Pedro)

Authors:

Melero, I. (Ignacio)

Berraondo, P. (Pedro)

Keywords:

4-1BB
T cell
Therapy

Issue Date:

2020

Publisher:

Rockefeller University Press

ISSN:

0022-1007

Note:

This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms/). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 4.0 International license, as described at https://creativecommons.org/licenses/by-nc-sa/4.0/).

Citation:

Melero, I. (Ignacio); Berraondo, P. (Pedro). "4-1BB (CD137) in anticancer chimeras". Journal of experimental medicine. 217 (12), 2020, e20201562

Abstract

4-1BB (CD137, TNFRSF9) mediates costimulatory signals important for activation and persistence of cytotoxic T lymphocytes. In this issue of JEM, Oda et al. (https://doi.org/10.1084/jem.20191166) report on a chimeric construction encompassing extracellular Fas and intracellular 4-1BB to dramatically improve adoptive T cell therapy.

URI:

https://hdl.handle.net/10171/66769

DOI:

10.1084/jem.20201562

Appears in Collections:

DA - CIMA - Inmunología e inmunoterapia - Inmunología del cáncer - Artículos de revista

Files in This Item: